We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
- Authors
Cunningham, David; Chau, Ian; Stocken, Deborah D; Valle, Juan W; Smith, David; Steward, William; Harper, Peter G; Dunn, Janet; Tudur-Smith, Catrin; West, Julia; Falk, Stephen; Crellin, Adrian; Adab, Fawzi; Thompson, Joyce; Leonard, Pauline; Ostrowski, Joe; Eatock, Martin; Scheithauer, Werner; Herrmann, Richard; Neoptolemos, John P
- Abstract
Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 33, p5513
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.24.2446